<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012141</url>
  </required_header>
  <id_info>
    <org_study_id>AU 793</org_study_id>
    <nct_id>NCT01012141</nct_id>
  </id_info>
  <brief_title>Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer</brief_title>
  <acronym>PROTAXY</acronym>
  <official_title>Pilot Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First Line Treatment of Hormone Independent Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE : Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary&#xD;
      supplements, such as phytochemicals, may stop or delay the development of prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the pathological response rate in metastatic prostate&#xD;
      cancer patients treated by : Docetaxel with a phytochemical&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as assessed by clinical, biological and paraclinical examination</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the best neuroendocine markers between chromogranin A (CgA), neuron-specific enolase (NSE) and serotonin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression as assessed by RECIST criteria and PSA level</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess compliance of per os phytonutrient treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment impact on compliance</measure>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>phytochemical</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Patients receiving androgen-suppressive therapy in the form of chirurgical castration&#xD;
             by orchiectomy or pulpectomy,or medical by LHRH agonist or antagonist with or without&#xD;
             anti-androgen or all treatment blocking non gonadic testosterone fraction&#xD;
&#xD;
          -  Resulting to testosteronemia &lt;0,5 ng/ml&#xD;
&#xD;
          -  Histologically confirmed adenocarcinomia of prostate cancer and documented hormone&#xD;
             independant metastatic disease - defined by: objective progression with at least one&#xD;
             measurable lesion and/or evaluable lesion according to RECIST criteria and /or a rise&#xD;
             in PSA level (&quot;rising PSA&quot;)&#xD;
&#xD;
          -  Total bilirubin ≤ upper limit of normal (ULN).&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times ULN. Alkaline phosphatase ≤ 2.5 times ULN.&#xD;
&#xD;
          -  Serum creatinine &lt; 140 µmol/L or creatinine clearance &gt; 60 mL/ min.&#xD;
&#xD;
          -  Neutrophil count &gt; 2.109 L-1.&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3.&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Not previous chemotherapy, except Estracyt&#xD;
&#xD;
          -  No liver, kidney or heart failure link to treatment&#xD;
&#xD;
          -  No malabsorption syndrome or disease significantly affecting gastrointestinal function&#xD;
&#xD;
          -  Prior radiotherapies are permetted withing four weeks of the first study treatment and&#xD;
             must be &lt; 25 % of the bone marrow, and all adverse events must be resolved&#xD;
&#xD;
          -  Prior surgery are permitted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  History of psychiatric disorders including psychotic disorder, dementia or seizures&#xD;
             that would prohibit the understanding, observance and giving of informed consent&#xD;
&#xD;
          -  Previous or concomitant other malignancies except basal or squamous cell carcinoma of&#xD;
             the skin or other cancer curatively treated with surgery and/or radiotherapy&#xD;
&#xD;
          -  Patients should not have symptomatic brain metastasis&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled co-morbid medical condition&#xD;
&#xD;
          -  Malabsorption syndrome or disease significantly affecting gastro-intestinal function&#xD;
             or major resection of the stomach, proximal small bowel or grade &gt; 2 dysphagia&#xD;
&#xD;
          -  Patients with uncontrolled infection&#xD;
&#xD;
          -  History of significant neurologic (i.e. peripheral neuropathy grade &gt; 2 using NCI-CTC&#xD;
             criteria v3.0)&#xD;
&#xD;
          -  Patients should not have received NSAIDs or COX2 inhibitors within the three weeks&#xD;
             prior to starting the study&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days prior to registration&#xD;
&#xD;
          -  Patients should not have current regimen containing dietary phytonutrients&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Chollet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Jean Perrin</investigator_affiliation>
    <investigator_full_name>Philippe Chollet</investigator_full_name>
    <investigator_title>Pr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

